Fig. 2

CALML3 as a coregulator of ERα affects the expression of ZNF423 and BRCA1. a Interaction of ERα and CALML3 in ZNF423 rs9940645 WT or variant genotype breast cancer cells treated with 0.01 nM E2. Co-IP performed by immunoprecipitating the protein complex with anti-ERα antibody, followed by immunoblotting for CALML3, or vice versa. b–e CALML3 was knocked down in ERα + breast cancer cells homozygous for ZNF423 WT or variant SNP genotypes and followed by treatment with 0.01 nM E2 ± 4-OH-TAM/raloxifene 10^–7 mol/L. ZNF423 and BRCA1mRNA expression levels relative to beta-ACTN shown as the mean of three independent experiments (± SEM). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by two-tailed Student’s t test. Protein levels determined by western blot (WB) analysis. IP immunoprecipitation, 4-OH-TAM 4-hydroxytamoxifene, E2 estradiol, ERα estrogen receptor alpha, Ral raloxifene